Picture the situation: someone you love has just been diagnosed with a death sentence disease with no know treatment. The FDA just chose not to outlaw a promising but unproven new treatment for it. Now you get to choose whether to take it or not. And somehow the FDA are evil twisted bad guys!?
hmottestad|1 year ago
The FDA is definitely the evil and twisted bad guys if they can't stop snake oil sellers from stating that their products cure disease X just because the snake oil guy us friends with someone high up in the FDA.
otterley|1 year ago
cubefox|1 year ago
> One explanation for drug bans is that regulators know more than consumers about product quality. But why not just communicate the information in their ban, perhaps via a “would have banned” label? Because product labeling is cheap-talk, any small market failure tempts regulators to lie about quality, inducing consumers who suspect such lies to not believe everything they are told. In fact, when regulators expect market failures to result in under-consumption of a drug, and so would not ban it for informed consumers, regulators ex ante prefer to commit to not banning this drug for uninformed consumers.
https://philpapers.org/rec/HANWLA
derlvative|1 year ago
partitioned|1 year ago
jsbg|1 year ago
This is obviously false given the existing supplements business. The idea that we have a way to prevent people from being ripped off is naive. But even so, the "reason" for the FDA doesn't change its incentive structure: allowing a drug that kills a few people will reflect badly on it, while disallowing a drug that would have saved millions of lives likely would have little consequence for the decision makers.
doe_eyes|1 year ago
There is a weaker but still defensible argument that they should stop others from selling you flu medication that isn't proven to work. But one could imagine a less restrictive reality where such drugs simply must be labeled clearly and you make your own decisions. In fact, there's already a weird carve-out like that for "natural" substances, so you can for example buy artemisinin as a "supplement" if you want to...
But what's the humane argument for "protecting" people with terminal or otherwise devastating diseases from trying drugs that can plausibly work, and were created by people acting in good faith, and that had some clinical trials done, but the trials weren't as thorough as a committee wanted them to?
"Yeah, he died, but at least we stopped him from potentially wasting some money."
freedomben|1 year ago
Now that said, I have a huge problem with this skipping. FDA rules need to be applied consistently and follow the process. I'm sympathetic to the desired outcome, but the problem is the system is set up as a gatekeeper. Fix the system, don't try to hack around it like this. That just further undermines trust and faith in the system.
dabraham1248|1 year ago
Well, among other things, if anyone makes money selling colored water, it encourages others to sell colored water. It also encourages companies that are trying to sell actual drugs to skip that expensive "testing" phase. Bad money usually chases out the good (https://en.wikipedia.org/wiki/Gresham's_law) so it's likely that we will devolve into a system where very few drugs are adequately tested.
I'm not saying it never happens, but if a law, policy, or agency reduces big corporation profits, then it's almost always because lots of people were dying.
michaelmrose|1 year ago
For the horrible things at the edge of treatability and beyond there are always many promising ideas most of them worthless or bad and the price people are willing to pay is either all their money or all everyone's money depending on whether insurance covers it.
If you don't allow insurance to cover it then only a handful of rich folks get soaked but this is politically difficult to maintain.
tchalla|1 year ago
thayne|1 year ago
Is it perfect? No. Could it be improved? Yes. But the rules exist for a reason.
ooterness|1 year ago
goldpizza44|1 year ago
The question is who is paying for these treatments? Drug companies are not shy about charging tens of thousands of dollars a year for a course of treatment that may or may not help. Insurance companies and Medicare partD will probably be reluctant to reimburse. Drug companies have large incentives to get patients to pay out of pocket, and no, they won't refund if the product is not effective.
Perhaps if the FDA were to create a new class of approval that states: Drugs under this class are shown to not cause harm but are also not proven to be helpful. They may be taken, but drug companies may not charge for supplies until efficacy is shown in controlled conditions.
The primary issue here is there are plenty of Snake Oil salesmen ready to tell you anything you want to hear and have no qualms about taking "somebody's" money.
I am sure creating a new class such as this, will also create a host of unintended consequences though.
devmor|1 year ago
A person facing death from disease is desperate, and desperate people are easily taken advantage of. This is part of the reason the FDA exists - to protect desperate people from being ripped off.
The FDA can and should prevent unproven medicines that are not ready for human trials from being used without due diligence.
Klinky|1 year ago
jostmey|1 year ago
derlvative|1 year ago
Aurornis|1 year ago
> The real problem is that it costs too much to bring new treatments through a clinical trial
As opposed to what? Just letting anything go? We basically have that situation in the alternative medicine world and the grifters are out in full force peddling things that we know don’t work the way they claim. Imagine how bad it would be if we waived away clinical trial requirements.
lavelganzu|1 year ago
n4r9|1 year ago
> [Sarepta's] gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial
https://www.statnews.com/2023/10/30/sareptas-duchenne-gene-t...
> the drug failed a large, Phase 3 trial last year ... three review teams ... wrote that the data Sarepta submitted "cast significant uncertainty regarding the benefits of the treatment".
https://www.statnews.com/2024/06/20/sarepta-duchenne-elevidy...
I'm not sure what makes this treatment "promising" other than the gushings of the CEO. Are you arguing that we should give new treatments a free pass on regulations as long as its for a death-sentence disease and the CEO has connections?
bedhead|1 year ago
These should be approved on the condition that the patients pay into escrow and get refunded one day if the drug fails trials.
amluto|1 year ago
IMO the actual failure here is the fact that Sarepta can charge $3.2M for a product without demonstrated efficacy.
redserk|1 year ago
pama|1 year ago
JumpCrisscross|1 year ago
derlvative|1 year ago
makmanalp|1 year ago
It's easy to yell paternalism but this doesn't look like a case of paper pushers getting in the way of a promising drug to me. Also, history is littered with examples of why "buyer beware" does NOT work, and a vast literature on information asymmetry, adverse selection, "The Market for Lemons", etc etc. Also, the FDA already has mechanisms to speed up new drugs getting to patients when the benefit is clear early on, AFAIK.
unknown|1 year ago
[deleted]
actinium226|1 year ago
[deleted]
jobs_throwaway|1 year ago
kaibee|1 year ago